285 related articles for article (PubMed ID: 32001241)
41. [Progress on medication-related osteonecrosis of the jaw].
Wang QZ; Liu JY; Pan J
Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354
[TBL] [Abstract][Full Text] [Related]
42. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
43. Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions.
Moreno Rabie C; Cavalcante Fontenele R; Oliveira Santos N; Nogueira Reis F; Van den Wyngaert T; Jacobs R
Dentomaxillofac Radiol; 2023 Nov; 52(8):20230238. PubMed ID: 37874081
[TBL] [Abstract][Full Text] [Related]
44. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
45. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
46. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
Carlson ER; Basile JD
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
[TBL] [Abstract][Full Text] [Related]
47. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Thomas C; Spanidis M; Engel C; Roos FC; Frees S; Neisius A; Hampel C; Rubenwolf P; Thüroff JW; Walter C; Miederer M
Clin Oral Investig; 2016 May; 20(4):753-8. PubMed ID: 26307268
[TBL] [Abstract][Full Text] [Related]
48. Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.
Heim N; Götz W; Kramer FJ; Faron A
Dentomaxillofac Radiol; 2019 Dec; 48(8):20190132. PubMed ID: 31530019
[TBL] [Abstract][Full Text] [Related]
49. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
[TBL] [Abstract][Full Text] [Related]
50. Radiographic Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) With Different Primary Cancers and Medication Therapies.
Muttanahally KS; Tadinada A
Cureus; 2023 Aug; 15(8):e42830. PubMed ID: 37664344
[TBL] [Abstract][Full Text] [Related]
51. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
Gavaldá C; Bagán JV
Med Oral Patol Oral Cir Bucal; 2016 May; 21(3):e260-70. PubMed ID: 26827066
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
53. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).
Aguirre JI; Castillo EJ; Kimmel DB
Bone; 2021 Dec; 153():116184. PubMed ID: 34520898
[TBL] [Abstract][Full Text] [Related]
54. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Marcianò A; Guzzo GM; Peditto M; Picone A; Oteri G
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33353034
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonate-related osteonecrosis of the jaw.
Wilde F; Heufelder M; Lorenz K; Liese S; Liese J; Helmrich J; Schramm A; Hemprich A; Hirsch E; Winter K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):804-11. PubMed ID: 23159120
[TBL] [Abstract][Full Text] [Related]
56. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
[TBL] [Abstract][Full Text] [Related]
57. Medication-related osteonecrosis of the jaws: a single centre, Far North Queensland case series.
Smith S; Finn B; Goss AN
Aust Dent J; 2022 Jun; 67(2):168-171. PubMed ID: 35199861
[TBL] [Abstract][Full Text] [Related]
58. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws.
Klingelhöffer C; Zeman F; Meier J; Reichert TE; Ettl T
J Craniomaxillofac Surg; 2016 Oct; 44(10):1694-1699. PubMed ID: 27591091
[TBL] [Abstract][Full Text] [Related]
60. Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws.
Soundia A; Hadaya D; Mallya SM; Aghaloo TL; Tetradis S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Dec; 126(6):537-544. PubMed ID: 30266375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
